New Drug Application For Rasilez®, An Innovative Oral Renin Inhibitor To Treat High Blood Pressure, Accepted For US Regulatory Review

... Novartis announced that the US Food and Drug Administration (FDA) accepted its application for Rasilez (aliskiren) as a treatment for high blood pressure. As a renin inhibitor, Rasilez would represent the first new treatment approach for people with high blood pressure in more than a decade. European submission remains on track for 2006... click link for more info. ...